Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs
Stockchase Opinions

John ZechnerBiomiraBRA.TODON'T BUYMay 18, 2001

Doesn't have top line growth. Some products in 3rd phase. Speculative.
$11.08

Stock price when the opinion was issued

biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

SELL
Not a fan of biotech stocks. Difficult to read with all the little points of approval or non-approval. With the big spike, don't buy.
TOP PICK
The entire energy sector is an interesting play. There has been a shrinkage of capacity in the last several years.
DON'T BUY
Outlook is anybody's guess. No earnings.
DON'T BUY
Will take a while. Prefers Isotechnica,
BUY ON WEAKNESS
RISKY. No earnings. Treat as a trading stock between $5 and $7.
BUY
Good long term investment, but prefers MDS.
DON'T BUY
Great product, but company has had problems.
DON'T BUY
Biotechs out of favour. Has broken $6.40. Next level is $3.90.
WAIT
Taking a long time to get to market.
BUY ON WEAKNESS
In phase 3 and has partnered with Merk.
BUY
Smart mngmnt. Good sector. Big litigation risk re: patents/class action suits in pharmaceuticals.
BUY
Good company. Drugs in 3rd phase. Short term should do well. Getting a new partner
BUY ON WEAKNESS
A very active/volatile stock. Lots of press
DON'T BUY
Difficult to select which bio company but prefers BioChem or a fund